Biana Godin

Biana Godin, MScPharm, PhD

Associate Professor of Nanomedicine, Academic Institute
Associate Member, Research Institute
Houston Methodist
Weill Cornell Medical College

Research Lab


Dr. Biana Godin earned her Ph.D. in Pharmaceutical Sciences from the Hebrew University of Jerusalem in 2006. During her Ph.D. studies, Dr. Godin focused on designing a non-invasive treatment for the hard-to-treat skin deep infections and on nasal delivery of proteins. She was recruited as a Postdoctoral trainee in the field of Cancer Nanotechnology to the University of Texas Health Sciences Center. Her postdoctoral research focused on injectable multistage nanovectors (MSVs) for cancer treatment and imaging. Her work provided insightful understanding of the interactions of MSVs with immune cells in vivo and in vitro, biocompatibility of MSV, effect of geometry and targeting moieties on MSV biodistribution, and evaluation of MSV systems as near-infra red and MRI imaging agents. In October 2010, Dr. Godin joined the Department of Nanomedicine at the Research Institute. 

Research in Dr. Godin's lab, largely funded by federal and foundation grants, focuses on developing physiologically relevant in vitro and in vivo disease models and exploiting physical and biological mechanisms to improve currently available therapeutic options in oncology and obstetrics. Dr. Godin considers herself a translational scientist on the interception of biological and physical sciences, with the ultimate goal of bringing advanced and safe therapies and the techniques to personalize therapies into the clinic to benefit patients.

Dr. Godin has more than 200 scientific publications, received multiple federal and foundation-based grants and participated in multiple national and international grant review panels. 

Dr. Godin and her group published numerous peer-reviewed articles, book chapters and reviews in top journals including Nature Nanotechnology, Advanced Functional Materials, Journal of Controlled Release and Cancer Research. She also received national and international awards and other recognitions for her work and is on the editorial board and review board for numerous journals. 

Description of Research

Dr. Godin's research focuses primarily on the following areas:

-Employing principles of nanomedicine in Ob/Gyn

-Targeting liver metastasis with advanced nanocarriers

-Novel strategies to target tumor microenvironment

-Advanced patient-derived ex vivo disease models for personalized therapies

The main objective of these studies is to provide innovative approaches to treatment and diagnosis of cancer and Ob/Gyn disorders. 

Areas Of Expertise

Nanomedicine Cancer Physical sciences in oncology Obstetrics Nano-therapeutics targeting Ob/Gyn
Education & Training

Postdoctoral Fellowship, The Hebrew University of Jerusalem
PhD, The Hebrew University of Jerusalem
MSc Pharm, The Hebrew University of Jerusalem
Postdoctoral Fellowship, University of Texas Health Science Center at Houston

Sex-dependent improvement in traumatic brain injury outcomes after liposomal delivery of dexamethasone in mice
Baudo, G, Flinn, H, Holcomb, M, Tiwari, A, Soriano, S, Taraballi, F, Godin, B, Zinger, A & Villapol, S 2024, , Bioengineering and Translational Medicine.

Image-Guided Deployment and Monitoring of a Novel Tungsten Nanoparticle–Infused Radiopaque Absorbable Inferior Vena Cava Filter in a Swine Model
San Valentin, EM, Damasco, JA, Bernardino, M, Court, KA, Godin, B, Canlas, GM, Melancon, A, Chintalapani, G, Jacobsen, MC, Norton, W, Layman, RR, Fowlkes, N, Chen, SR, Huang, SY & Melancon, MP 2024, , Journal of Vascular and Interventional Radiology, vol. 35, no. 1, pp. 113-121.e3.

Macrophage Checkpoint Nanoimmunotherapy Has the Potential to Reduce Malignant Progression in Bioengineered In Vitro Models of Ovarian Cancer
VandenHeuvel, SN, Chau, E, Mohapatra, A, Dabbiru, S, Roy, S, O’Connell, C, Kamat, A, Godin, B & Raghavan, SA 2024, , ACS Applied Bio Materials.

Modeling critical interaction for metastasis between circulating tumor cells (CTCs) and platelets adhered to the capillary wall
Milosevic, M, Simic, V, Nikolic, A, Shao, N, Kawamura Hashimoto, C, Godin, B, Leonard, F, Liu, X & Kojic, M 2023, , Computer Methods and Programs in Biomedicine, vol. 242, 107810.

Lysicamine Reduces Protein Kinase B (AKT) Activation and Promotes Necrosis in Anaplastic Thyroid Cancer
Rodrigues, MT, Michelli, APP, Caso, GF, de Oliveira, PR, Rodrigues-Junior, DM, Morale, MG, Machado Júnior, J, Bortoluci, KR, Tamura, RE, da Silva, TRC, Raminelli, C, Chau, E, Godin, B, Calil-Silveira, J & Rubio, IGS 2023, , Pharmaceuticals, vol. 16, no. 12, 1687.

Image-guided deployment and monitoring of a novel tungsten nanoparticleâ€"infused radiopaque absorbable inferior vena cava filter in pigs
San Valentin, EM, Damasco, JA, Bernardino, M, Court, KA, Godin, B, Canlas, GM, Melancon, A, Chintalapani, G, Jacobsen, MC, Norton, W, Layman, RR, Fowlkes, N, Chen, SR, Huang, SY & Melancon, MP 2023, , bioRxiv.

Rosuvastatin-Eluting Gold Nanoparticle-Loaded Perivascular Implantable Wrap for Enhanced Arteriovenous Fistula Maturation in a Murine Model
Klusman, C, Martin, B, Perez, JVD, Barcena, AJR, Bernardino, MR, San Valentin, EMD, Damasco, JA, Mundo, HCD, Court, K, Godin, B, Fowlkes, N, Bouchard, R, Cheng, J, Huang, SY & Melancon, MP 2023, , bioRxiv.

Rosuvastatin-Eluting Gold-Nanoparticle-Loaded Perivascular Wrap for Enhanced Arteriovenous Fistula Maturation in a Murine Model
Klusman, C, Martin, B, Perez, JVD, Barcena, AJJR, Bernardino, MR, Valentin, EMDS, Damasco, JA, Del Mundo, HC, Court, KA, Godin, B, Canlas, GM, Fowlkes, N, Bouchard, R, Cheng, J, Huang, SY & Melancon, MP 2023, , Advanced Fiber Materials, vol. 5, no. 6, pp. 1986-2001.

Telomerase mRNA Enhances Human Skin Engraftment for Wound Healing
Chang, DF, Court, KA, Holgate, R, Davis, EA, Bush, KA, Quick, AP, Spiegel, AJ, Rahimi, M, Cooke, JP & Godin, B 2023, , Advanced Healthcare Materials, vol. 13, no. 2, 2302029, pp. e2302029.

Macrophage Activation in the Ovarian Cancer Tumor Microenvironment and Design of a Novel Immunotherapy
OConnell, C, Chau, E, Vasquez, M, VandenHeuvel, S, Kamat, AA, Raghavan , S & Godin, B 2023, , Society of Gynecologic Oncology Winter Meeting, Whistler, Canada, 2/2/23 - 2/4/23.

mRNA Expression and Delivery Efficacy of Lipid Nanoparticles in the Cells Breast Tumor Microenvironment: In Vitro and In Vivo Evaluation.
Court, KA, Chau, E, Cooke, JP & Godin, B 2022, , San Antonio Breast Cancer Symposium, San Antonio, United States, 12/6/22.

CD44 receptor targeted nanoparticles augment immunity against tuberculosis in mice
Singh, VK, Chau, E, Mishra, A, DeAnda, A, Hegde, VL, Sastry, JK, Haviland, D, Jagannath, C, Godin, B & Khan, A 2022, , Journal of Controlled Release, vol. 349, pp. 796-811.

The Proteolytic Landscape of Ovarian Cancer: Applications in Nanomedicine
O’Connell, C, VandenHeuvel, S, Kamat, A, Raghavan, S & Godin, B 2022, , International journal of molecular sciences, vol. 23, no. 17, 9981.

Heat-induced SIRT1-mediated H4K16ac deacetylation impairs resection and SMARCAD1 recruitment to double strand breaks
Chakraborty, S, Singh, M, Pandita, RK, Singh, V, Lo, CSC, Leonard, F, Horikoshi, N, Moros, EG, Guha, D, Hunt, CR, Chau, E, Ahmed, KM, Sethi, P, Charaka, V, Godin, B, Makhijani, K, Scherthan, H, Deck, J, Hausmann, M, Mushtaq, A, Altaf, M, Ramos, KS, Bhat, KM, Taneja, N, Das, C & Pandita, TK 2022, , iScience, vol. 25, no. 4, 104142, pp. 104142.

Multiple breast cancer liver metastases response to macrophage-delivered nanotherapy evaluated via a 3D continuum model
Goodin, DA, Chau, E, Tiwari, A, Godin, B & Frieboes, HB 2023, , Immunology, vol. 169, no. 2, pp. 132-140.

Lipid Nanoparticles Designed to Disrupt the CD47-SIRPa Signaling Axis in Ovarian Cancer
Godin, B & Chau, E 2022, , Houston Methodist Neal Cancer Center 2022 Cancer Center Retreat, Houston, TX. houston, United States, 1/1/22.

Modeling of Nanotherapy Response as a Function of the Tumor Microenvironment: Focus on Liver Metastasis
Frieboes, HB, Raghavan, S & Godin, B 2020, , Frontiers in Bioengineering and Biotechnology, vol. 8, 1011, pp. 1011.

Nonlinear response to cancer nanotherapy due to macrophage interactions revealed by mathematical modeling and evaluated in a murine model via CRISPR-modulated macrophage polarization
Leonard, F, Curtis, LT, Hamed, AR, Zhang, C, Chau, E, Sieving, D, Godin, B & Frieboes, HB 2020, , Cancer Immunology, Immunotherapy, vol. 69, no. 5, pp. 731-744.

Design and in vitro characterization of multistage silicon-PLGA budesonide particles for inflammatory bowel disease
Leonard, F, Srinivasan, S, Liu, X, Collnot, EM, Ferrari, M, Lehr, CM & Godin, B 2020, , European Journal of Pharmaceutics and Biopharmaceutics, vol. 151, pp. 61-72.

Pre-existing H4K16ac levels in euchromatin drive DNA repair by homologous recombination in S-phase
Horikoshi, N, Sharma, D, Leonard, F, Pandita, RK, Charaka, VK, Hambarde, S, Horikoshi, NT, Khaitan, PG, Chakraborty, S, Cote, J, Godin, B, Hunt, CR & Pandita, TK 2019, , Communications Biology, vol. 2, no. 1, 253.